Moody's Downgrades Valeant Pharma (VRX) CFR to B3 from B2; Outlook Negative

S&P Affirms Rating on Valeant Pharma (VRX) Amid Weak Q3 Report, Cut Outlook

S&P Global Ratings said its ratings and outlook on Valeant Pharmaceuticals International Inc. (NYSE: VRX) (B/Stable/--) are unchanged following the company's weak earnings report for the third quarter and lowered guidance for 2016. The company also indicated 2017 performance will likely be weaker than in 2016, because of the loss of exclusivity on certain neurology products. This contrasts with our prior expectation that 2017 would be materially stronger than 2016, given that 2016 has been a year of significant turbulence and transition for the company.

This represents a significant deterioration from our expectations and we are lowering our... More

Aegis Affirms Progenics Pharma (PGNX) at 'Buy'; Solid Relistor Results Fuel Q3 Revenue Gains (VRX)

Aegis Capital affirms Progenics Pharma (Nasdaq: PGNX) at Buy with a price target of $11 following Q3 results issued on Monday

3Q revenues were driven by the approval (which triggered a $50 million milestone by Valeant Pharmaceuticals) and US launch of oral... More

Valeant Pharmaceuticals (VRX) volatility stays elevated after less than expected Q3 and outlook

Valeant Pharma (NYSE: VRX) November weekly call option implied volatility is at 142, November is at 116, December is at 95; compared to its 52-week range of 53 to 173 after reporting less than expected Q3 results and outlook

Guggenheim Remains Positive on Valeant (VRX) post Q3: 'In the Kitchen Sink, but Not Down the Drain'

Guggenheim analyst Louise Chen weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the company reported, as expected, a 3Q16 miss and lowered its '16 EPS guidance.

Chen commented, "VRX has noted since its 1Q16 call that the business should start to recover in 2H16. Evidence of this was demonstrated in 3Q16 as VRX reported sequential improvements in sales and EBITDA throughout the year. Therefore, despite the miss and... More

Valeant Pharma (VRX) Sees Solid Bounce Off Morning Lows

Valeant Pharma (NYSE: VRX) has moved solidly off morning lows but remains down 20.5% to $15.21. Shares were down as much as 28% to $13.77 earlier.

The bounce could be short covering.

Biggest Takeaway from Valeant (VRX) Call is 2017 Revs and EBITDA Expected to Be Below 2016 - Evecore ISI's Raffat

Evecore ISI analyst Umer Raffat said by far the biggest takeaway from Valeant Pharma (NYSE: VRX) call is that 2017 revenues and EBITDA is expected to be below 2016. The CFO flagged generic competition against Isuprel, Virazole, Syprine, Mephyton etc.

Raffat said the single... More

FDA Posts Valeant Pharma (VRX) Warning Letter Related to Rochester Plant

FDA posts warning letter issued to Valeant Pharma (NYSE: VRX) related to its Rochester plant.

Mr. Joseph C. Papa, Chairman and CEO
Valeant Pharmaceuticals International
400 Somerset Corporate Blvd.
Bridgewater, New Jersey 08807
FEI: 3009443653

Dear Mr. Papa:

During an inspection of your firm located in Rochester, NY, on August 23, 2016 through September 1, 2016, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer and distributor of the Small Particle Size Aerosol Generator, (SPAG-2), a nebulizer pneumatic flow system for the administration... More

Pre-Open Stock Movers 11/08: (PERI) (ACAD) (MOMO) Higher; (HTZ) (KND) (VRX) (CVS) Lower (more...)

Today's Pre-Open Stock Movers

Hertz Global (NYSE: HTZ) 40.9% LOWER; reported Q3 EPS of $1.58, $1.17 worse than the analyst estimate of $2.75. Revenue for the quarter came in at $2.5 billion versus the consensus estimate of $2.6 billion. GUIDANCE: Hertz Global sees FY2016 EPS of $0.51-$0.88, versus the consensus of $2.94.

Kindred Healthcare (NYSE: KND) 33.1% LOWER; reported Q3 EPS of $0.05, $0.01 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $1.79 billion versus the consensus estimate of $1.77 billion. GUIDANCE: Kindred Healthcare sees FY2016... More

Valeant Pharma (VRX) says ex-CEO Pearson is still consulting in 'limited' capacity - Conf. call

Valeant Pharma (NYSE: VRX) says ex-CEO Mike Pearson is still consulting in 'limited' capacity, according to the company's conference call on Tuesday.

Valeant Pharma (VRX) Sinks 27% in Pre-Open Trade, Falling Below $14

Valeant Pharma (NYSE: VRX) is free-fall pre-open. Shares are down 27% to $13.92.

Valeant (VRX) Misses, Lowers, Delays - Wells Fargo's Maris

Wells Fargo analyst David Maris offered some comments on Valeant Pharmaceuticals (NYSE: VRX) following its Q3 miss and lower outlook.

Maris commented, "Valeant reported 3Q results that missed expectations. Revenue of $2.48 billion missed our estimate of $2.74 billion and consensus of $2.51 billion. Valeant's adjusted EPS of $1.55 missed our $1.95 estimate and consensus of $1.75. We had assumed Valeant would experience some tailwinds from pricing, higher rebates, and increased prior-authorizations; however, it appears... More

Valeant (VRX) Miss and Guide Down Expected, But Magnitude Maybe Not - Mizuho

Mizuho Securities analyst Irina Koffler weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the 3Q:16 miss and lowered guide, which were widely expected but perhaps the magnitude was not.

Koffler commented, "Valeant reported $2.48B in revenues and non-GAAP EPS of $1.55 vs. $2.51B and $1.75 StreetAccount... More

Valeant (VRX) Q3 a Mixed Bag, Guidance Cut on Higher Side of Expectations - BMO

BMO Capital analyst Gary Nachman weighed in on Valeant Pharmaceuticals (NYSE: VRX) following mixed Q3 results and 2016 guidance reset.

Nachman commented, "VRX reported 3Q revenue of $2,480mn vs. our/consensus of $2,463/2,511mn. Adj. EPS was $1.55 vs. our/consensus of $1.65/1.75. The quarter was mixed, with a lot of moving parts.... More

Valeant Pharma (VRX) EBITDA Was North of $1B, Which Was Better than Feared - Evecore ISI Raffat

Evecore ISI analyst Umer Raffat weighed in on Valeant Pharma (NYSE: VRX) quarter. He notes that based on his investor conversations, buyside sentiment had MASSIVELY shifted when the stock moved from ~$30 to... More

Valeant Pharma (VRX) Misses Q3 EPS by 20c, Cuts FY16 Outlook

Valeant Pharma (NYSE: VRX) reported Q3 EPS of $1.55, $0.20 worse than the analyst estimate of $1.75. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.49 billion.

"This past quarter, we made further progress toward establishing the new Valeant," said Joseph C.... More